Medicinal association of a biguanine and a carrier, for example metformin and arginine

a biguanine and carrier technology, applied in the field of medicine combination, can solve the problem of low bioavailability

Inactive Publication Date: 2007-11-15
INOPHARM
View PDF2 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013] Thus, the results obtained according to the invention, on experimental models of diabetes, have shown that metformin active compounds having, within their structure, an arginine residue, were capable of increasing the bioavailability of the metformin, in an unexpected manner, by potentiating its effects against hyperglycemia, which is the main symptom of diabetes.

Problems solved by technology

This low bioavailability explains the bothersome side effect of metformin, namely diarrhea.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal association of a biguanine and a carrier, for example metformin and arginine
  • Medicinal association of a biguanine and a carrier, for example metformin and arginine
  • Medicinal association of a biguanine and a carrier, for example metformin and arginine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0044] The expression “biguanide” is understood to mean in particular N-dimethylbiguanides, substituted or otherwise, and for example metformin, but also other pharmaceutical compounds, for example buformin or fenformin.

[0045] Preferably, the biguanide is metformin.

[0046] The expression “simultaneous administration” is intended to mean the administration, in a single dose, of the two active principles, it being understood that the simultaneous administration allows the release, in the organism, of the two active principles simultaneously or in sequence.

[0047] The term “biogenic” is intended to mean a chemical compound which is of natural or unnatural origin and / or is metabolizable and / or is biodegradable and / or is atoxic with respect to the human or the animal, at a physiological dose.

[0048] The term “transporter” is intended to mean a molecule or substance which allows the transfer of another molecule across a barrier, either by forming an attachment, or without forming an atta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

A medicinal combination for the treatment of diabetes, in particular of type 2 diabetes, combining a biguanide, in particular an N-dimethylbiguanide, as a first medicament, and an agent for transporting the said biguanide, as a second medicament, said combination comprising: e [sic] a therapeutically active quantity of the biguanide f [sic] and a quantity of transporting agent, previously determined to potentiate the therapeutic activity of the biguanide according to (a).

Description

[0001] This is a Divisional of application Ser. No. 10 / 465,997, filed Oct. 3, 2003, which in turn is a National Stage Application of PCT / FR01 / 04235, filed Dec. 31, 2001, which in turn claims the benefit of French Patent Application No. 00 / 17332, filed Dec. 29, 2000. The entire disclosure of the prior applications is hereby incorporated by reference herein in their entirety.FIELD OF THE INVENTION [0002] The present invention relates to a medicinal combination of two active principles, having, jointly, a complementary and / or synergistic action, this being for the treatment of diabetes, in particular of type 2 diabetes. [0003] The expression “complementary action” is intended to mean the pharmacological action of two different compounds making it possible to act on the same pathology via two respectively different pharmacological mechanisms, for example the combined use of two antidiabetic agents, such as a biguanide and a sulfonylurea. [0004] The expression “synergistic action” is int...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/155A61K31/195A61K47/48A61P3/10A61P5/00A61P9/00C07C279/22C07C279/26
CPCA61K31/155A61K31/195A61K47/48023A61K2300/00A61K47/54A61P3/10A61P5/00A61P9/00
Inventor RAPIN, JEAN-ROBERTHALBITTE, DOMINIQUE
Owner INOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap